Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Certolizumab pegol biosimilar - Xbrane

Next Previous
Drug Profile

Certolizumab pegol biosimilar - Xbrane

Alternative Names: AVT-10; BIIB-801; XB-003; Xcimzane

Latest Information Update: 07 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xbrane
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Fab fragments; Monoclonal antibodies; Nootropics; Polyethylene glycols
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Ankylosing spondylitis; Crohn's disease; Psoriasis; Rheumatoid arthritis; Spondylitis

Most Recent Events

  • 01 Jul 2025 Alvotech and ADVANZ PHARMA agree to co-develop certolizumab pegol biosimilar in Europe
  • 04 Jun 2025 Alvotech completes acquisition of Xbrane R&D Organisation
  • 20 Mar 2025 Alvotech acquires Certolizumab pegol biosimilar from Xbrane

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top